Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors

Inclusion Criteria: * Histologically confirmed malignant solid tumor * Advanced disease, meeting both of the following criteria: Metastatic or unresectable disease and standard curative or palliative measures do not exist or are no longer effective. * No known active brain metastases * Life expectancy \> 3 months * ECOG performance status 0-2 * Bilirubin normal * No uncontrolled intercurrent illness including, but not limited to, any of the following: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness or social situation that would limit study compliance. * Negative pregnancy test * Fertile patients must use effective contraception * Recovered from prior therapy * No prior chemotherapy within the past 4 weeks (6 weeks for nitrosoureas or mitomycin C). * No prior targeted therapy within the past 4 weeks * No prior immunotherapy within the past 4 weeks * No prior radiotherapy within the past 4 weeks. * No more than 2 prior chemotherapy regimens for advanced solid tumors. * No other concurrent investigational agents. Bisphosphonate therapy (e.g., pamidronate or zolendronate) is not considered investigational therapy. * No concurrent antiretroviral therapy for HIV-positive patients. * No other concurrent anticancer agents or therapies. * Tumor has spread to other parts of the body or cannot be removed by surgery. * More than 4 weeks since chemotherapy, biological therapy, or radiation therapy. * No more than two previous chemotherapy regimens for advanced solid tumor. * WBC \>= 3,000/mm\^3 * Platelet count \>= 100,000/mm\^3 * Creatinine clearance \>= 60 mL/min * Absolute neutrophil count \>= 1,500/mm³ * AST and ALT =\< 2.5 times upper limit of normal * No prior cumulative cisplatin dose \> 300 mg/m\^2 * No preexisting neuropathy \<= grade 2 * Not pregnant or nursing